All In Biotech

Drug Trial Radar · NCT05054439

A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC

A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

45

Actual

Start

Dec 22, 2021

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Sep 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase IIa study is a clinical trial to evaluate the safety and efficacy of SI-B001 in combination with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) who have experienced disease progression or intolerance to prior anti-PD-1 monoclonal antibody therapy with or without platinum-based chemotherapy, and who have received no more than second-line treatment.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • SI-B001Drug

    Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.

  • PaclitaxelDrug

    The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.

  • docetaxelDrug

    Docetaxel is administered at a dose of 35 mg/m² on Days 1, 8, and 15, with a 4-week treatment cycle. Treatment is continued until disease progression, unacceptable toxicity, or other reasons for discontinuation (such as withdrawal of informed consent or death).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: Up to 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • The Affiliated Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Union Hospital Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Shanghai Oriental Hospital

    Shanghai, Shanghai Municipality, China

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.